Robert W. Shafer

Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.

R. Shafer, D. Vuitton, R W Shafer, 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.

R. Shafer, C. Petropoulos, M. Winters, 2011, Antiviral research.

A Highly Divergent Picornavirus in a Marine Mammal

R. Shafer, P. Simmonds, E. Delwart, 2007, Journal of Virology.

Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe

D. Katzenstein, T. Merigan, R. Shafer, 1997, Journal of virology.

Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors

T. Merigan, R. Shafer, M. Winters, 1996, Antimicrobial agents and chemotherapy.

Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

L. Demeter, R. Reichman, P. Meehan, 2000, Antimicrobial Agents and Chemotherapy.